Head-to-head · Value Score
CoreAge Rx vs Bon Health
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Bon Health a 76. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameBon Health
#110 · Grade B- · Fair Price
Est. first month
From $120/mo (12-month plan, compounded)
Save ~91% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 76 — an est. $99/mo first month, with no teaser step-up baked in. Bon Health isn't out of it: Shoppers wanting transparent, no-membership compounded GLP-1 with physician-titrated dosing.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Bon Health |
|---|---|---|
| Value Score | 93 (A+) | 76 (B-) |
| Est. first month | $99/mo | From $120/mo (12-month plan, compounded) |
| Save vs brand-name | ~89% | ~91% |
| Semaglutide | $99/mo | From $120/mo (12-month plan, compounded) |
| Tirzepatide | $149/mo | From $170/mo (12-month plan, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Not disclosed |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Bon Health
Bon Health is a physician-led GLP-1 weight-loss telehealth service offering compounded semaglutide and tirzepatide on transparent commitment tiers — from $170/mo on the annual plan up to $330 month-to-month.
Why it's a deal
- Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
- Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
- 24/7 physician support included free with your order; 1-3 day rapid dispatch
- Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered
The fine print
- The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
- The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro button reads 'Coming Soon' and points back to the compounded version
- Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
- There is no readable terms page, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be checked before paying
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Bon Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.